[Herceptin (trastuzumab)].
Trastuzumab is a recombinant humanized monoclonal antibody directed against HER2. Several issues about its optimal use,mechanism of action or resistance still await convincing answers. Results of large-scale randomized trials and preclinical study might answer these questions. This review summarizes current knowledge about trastuzumab treatment.
Yamashiro
Hiroyasu
H
Dept.of Surgery, Graduate School of Medicine, Kyoto University, Japan.
Toi
Masakazu
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D013274:Stomach Neoplasms / Q000737:chemistry / Q000188:drug therapy; D015996:Survival Rate; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab